PLX - Protalix BioTherapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3094
-0.0057 (-1.81%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.3151
Open0.0000
Bid0.0000 x 2200
Ask0.0000 x 800
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume1,148,785
Market Cap46M
Beta (3Y Monthly)2.74
PE Ratio (TTM)N/A
EPS (TTM)-0.1620
Earnings DateNov 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.05
  • PR Newswire

    Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split

    Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that, at the Company's Special Meeting of Stockholders, its stockholders approved an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of 1‑for‑10 and to reduce the total number of authorized shares of the common stock from 350 million shares to 120 million shares.

  • Hedge Funds Watching Protalix BioTherapeutics Inc. (PLX) From Afar
    Insider Monkey

    Hedge Funds Watching Protalix BioTherapeutics Inc. (PLX) From Afar

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • PR Newswire

    Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease

    Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will host a key opinion leader (KOL) meeting on pegunigalsidase alfa, or PRX‑102, the Company's lead drug candidate for the treatment of Fabry Disease, in New York City on Monday, December 2, 2019, at 8:00 a.m. EST.

  • Thomson Reuters StreetEvents

    Edited Transcript of PLX earnings conference call or presentation 7-Nov-19 1:30pm GMT

    Q3 2019 Protalix Biotherapeutics Inc Earnings Call

  • Protalix Finalizes Accelerated Approval Pathway for PRX-102
    Zacks

    Protalix Finalizes Accelerated Approval Pathway for PRX-102

    Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.

  • PR Newswire

    Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

    CARMIEL, Israel, Nov. 18, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and its development and commercialization partner, Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi), today announced that they have completed a successful Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) regarding the Accelerated Approval pathway for pegunigalsidase alfa (PRX‑102) for the treatment of Fabry disease.

  • Some Protalix BioTherapeutics (NYSEMKT:PLX) Shareholders Have Taken A Painful 90% Share Price Drop
    Simply Wall St.

    Some Protalix BioTherapeutics (NYSEMKT:PLX) Shareholders Have Taken A Painful 90% Share Price Drop

    Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) shareholders should be happy to see the share price up 15% in the last...

  • Protalix (PLX) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Protalix (PLX) Reports Q3 Loss, Tops Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of 50.00% and 22.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

    CARMIEL, Israel, Nov. 7, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of ...

  • Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire

    Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019

    Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Oct. 29, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company ...

  • PR Newswire

    Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

    CARMIEL, Israel, Oct. 17, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced positive 12-month on-treatment data from the first 16 out of the 22 adult patients enrolled in its BRIDGE Phase III study. "We previously announced positive preliminary results from 16 patients after six months in the BRIDGE study in September 2018, and these new results, after 12 months of treatment, further suggest the strong potential benefit of pegunigalsidase alfa on renal function for Fabry patients," said Raul Chertkoff, M.D., Protalix's Vice President, Medical Affairs.

  • Protalix Completes Enrollment in Third Fabry Disease Study
    Zacks

    Protalix Completes Enrollment in Third Fabry Disease Study

    Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.

  • PR Newswire

    Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and its development and commercialization partner, Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced the completion of enrollment in their Phase III BALANCE clinical study of pegunigalsidase alfa, or PRX‑102, for the treatment of Fabry disease. The head-to-head Phase III BALANCE clinical study is designed to evaluate the safety and efficacy of PRX‑102 compared to agalsidase beta (Fabrazyme®) on renal function in Fabry patients with progressing kidney disease previously treated with agalsidase beta.

  • Thomson Reuters StreetEvents

    Edited Transcript of PLX earnings conference call or presentation 8-Aug-19 12:30pm GMT

    Q2 2019 Protalix Biotherapeutics Inc Earnings Call

  • GlobeNewswire

    Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

    CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins including a late-stage clinical product expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it received a deficiency letter from NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(a)(i) – (iii) of the NYSE American Company Guide (the “Company Guide”) as it has reported a stockholders’ equity deficiency as of June 30, 2019 and net losses in its five most recent fiscal years ended December 31, 2018.

  • Protalix BioTherapeutics, Inc. (NYSEMKT:PLX): Is Breakeven Near?
    Simply Wall St.

    Protalix BioTherapeutics, Inc. (NYSEMKT:PLX): Is Breakeven Near?

    Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses...

  • GlobeNewswire

    Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

    CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it has engaged a first-tier financial advisory firm to assist the Company in evaluating and pursuing strategic alternatives to maximize stakeholder value. Dror Bashan, Protalix’s President and Chief Executive Officer commented, “We have three key initiatives as a management team which include improving our capital structure, pursuing strategic partnerships and alliances and actively moving our pipeline toward commercialization.”  The Company also reported that it is actively pursuing potential partnering discussions for its other pipeline candidates, OPRX-106, an orally-delivered anti-inflammatory treatment, and alidornase alfa, a modified form of recombinant DNase (rhDNASE), as well as partnerships with other company’s compounds combined with Protalix’s ProCellEx® platform.

  • GlobeNewswire

    Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics

    Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA) today announced that Shlomo Yanai has resigned from the Company’s Board of Directors for personal reasons, effective today. Mr. Yanai has served on the Board of Directors and as the Company’s Chairman of the Board since July 2014. With the announcement of Mr. Yanai’s resignation, the Board of Directors unanimously elected Zeev Bronfeld, a current independent director, as Chairman of the Board.

  • Protalix (PLX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Protalix (PLX) Reports Q2 Loss, Tops Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 4.23%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update

    CARMIEL, Israel, Aug. 08, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019

    CARMIEL, Israel, July 29, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire

    Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer

    CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA) today announced that Eyal Rubin has been appointed to serve as the Company’s new Senior Vice President and Chief Financial Officer, effective September 22, 2019.  Yossi Maimon will continue to work with the Company’s finance and accounting teams to ensure a smooth transition of the Company’s financial and accounting functions until Mr. Rubin begins. “I am very happy to introduce Eyal to the Protalix team where he will bring valuable financial and accounting experience and knowledge,” said Dror Bashan, Protalix’s President and Chief Executive Officer.  “We wish Yossi success in his future endeavors.  Yossi has played a critical role in Protalix’s leadership enabling Protalix to advance our pipeline development during his tenure.

  • Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?
    Simply Wall St.

    Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?

    If you want to know who really controls Protalix BioTherapeutics, Inc. (NYSEMKT:PLX), then you'll have to look at the...